These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
325 related articles for article (PubMed ID: 31900258)
1. Epigenetic Targeting of Huang M; Zeki J; Sumarsono N; Coles GL; Taylor JS; Danzer E; Bruzoni M; Hazard FK; Lacayo NJ; Sakamoto KM; Dunn JCY; Spunt SL; Chiu B Cancer Res; 2020 Mar; 80(5):1024-1035. PubMed ID: 31900258 [TBL] [Abstract][Full Text] [Related]
2. Combining inhibitors of Brd4 and cyclin-dependent kinase can decrease tumor growth in neuroblastoma with MYCN amplification. Wood L; Huang M; Zeki J; Gong M; Taylor J; Shimada H; Chiu B J Pediatr Surg; 2021 Jul; 56(7):1199-1202. PubMed ID: 33838899 [TBL] [Abstract][Full Text] [Related]
5. BET inhibition silences expression of MYCN and BCL2 and induces cytotoxicity in neuroblastoma tumor models. Wyce A; Ganji G; Smitheman KN; Chung CW; Korenchuk S; Bai Y; Barbash O; Le B; Craggs PD; McCabe MT; Kennedy-Wilson KM; Sanchez LV; Gosmini RL; Parr N; McHugh CF; Dhanak D; Prinjha RK; Auger KR; Tummino PJ PLoS One; 2013; 8(8):e72967. PubMed ID: 24009722 [TBL] [Abstract][Full Text] [Related]
6. BET inhibitor suppresses melanoma progression Deng G; Zeng F; Su J; Zhao S; Hu R; Zhu W; Hu S; Chen X; Yin M Theranostics; 2020; 10(25):11428-11443. PubMed ID: 33052224 [No Abstract] [Full Text] [Related]
7. Polo-like Kinase-1 Regulates Myc Stabilization and Activates a Feedforward Circuit Promoting Tumor Cell Survival. Xiao D; Yue M; Su H; Ren P; Jiang J; Li F; Hu Y; Du H; Liu H; Qing G Mol Cell; 2016 Nov; 64(3):493-506. PubMed ID: 27773673 [TBL] [Abstract][Full Text] [Related]
8. AZD5153, a novel BRD4 inhibitor, suppresses human thyroid carcinoma cell growth in vitro and in vivo. Xu K; Chen D; Qian D; Zhang S; Zhang Y; Guo S; Ma Z; Wang S Biochem Biophys Res Commun; 2018 May; 499(3):531-537. PubMed ID: 29596834 [TBL] [Abstract][Full Text] [Related]
9. Targeted Therapy of Chen J; Nelson C; Wong M; Tee AE; Liu PY; La T; Fletcher JI; Kamili A; Mayoh C; Bartenhagen C; Trahair TN; Xu N; Jayatilleke N; Wong M; Peng H; Atmadibrata B; Cheung BB; Lan Q; Bryan TM; Mestdagh P; Vandesompele J; Combaret V; Boeva V; Wang JY; Janoueix-Lerosey I; Cowley MJ; MacKenzie KL; Dolnikov A; Li J; Polly P; Marshall GM; Reddel RR; Norris MD; Haber M; Fischer M; Zhang XD; Pickett HA; Liu T Clin Cancer Res; 2021 Mar; 27(5):1438-1451. PubMed ID: 33310889 [TBL] [Abstract][Full Text] [Related]
10. BRD4 amplification facilitates an oncogenic gene expression program in high-grade serous ovarian cancer and confers sensitivity to BET inhibitors. Rhyasen GW; Yao Y; Zhang J; Dulak A; Castriotta L; Jacques K; Zhao W; Gharahdaghi F; Hattersley MM; Lyne PD; Clark E; Zinda M; Fawell SE; Mills GB; Chen H PLoS One; 2018; 13(7):e0200826. PubMed ID: 30036377 [TBL] [Abstract][Full Text] [Related]
11. Dual BRD4 and AURKA Inhibition Is Synergistic against MYCN-Amplified and Nonamplified Neuroblastoma. Felgenhauer J; Tomino L; Selich-Anderson J; Bopp E; Shah N Neoplasia; 2018 Oct; 20(10):965-974. PubMed ID: 30153557 [TBL] [Abstract][Full Text] [Related]
12. Druggable epigenetic suppression of interferon-induced chemokine expression linked to Seier JA; Reinhardt J; Saraf K; Ng SS; Layer JP; Corvino D; Althoff K; Giordano FA; Schramm A; Fischer M; Hölzel M J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34016720 [TBL] [Abstract][Full Text] [Related]
13. Multiple CDK inhibitor dinaciclib suppresses neuroblastoma growth via inhibiting CDK2 and CDK9 activity. Chen Z; Wang Z; Pang JC; Yu Y; Bieerkehazhi S; Lu J; Hu T; Zhao Y; Xu X; Zhang H; Yi JS; Liu S; Yang J Sci Rep; 2016 Jul; 6():29090. PubMed ID: 27378523 [TBL] [Abstract][Full Text] [Related]
14. The TERT Promoter is Polycomb-Repressed in Neuroblastoma Cells with Long Telomeres. Graham MK; Xu B; Davis C; Meeker AK; Heaphy CM; Yegnasubramanian S; Dyer MA; Zeineldin M Cancer Res Commun; 2024 Jun; 4(6):1533-1547. PubMed ID: 38837897 [TBL] [Abstract][Full Text] [Related]
16. Targeting MYCN in neuroblastoma by BET bromodomain inhibition. Puissant A; Frumm SM; Alexe G; Bassil CF; Qi J; Chanthery YH; Nekritz EA; Zeid R; Gustafson WC; Greninger P; Garnett MJ; McDermott U; Benes CH; Kung AL; Weiss WA; Bradner JE; Stegmaier K Cancer Discov; 2013 Mar; 3(3):308-23. PubMed ID: 23430699 [TBL] [Abstract][Full Text] [Related]
17. Dual targeting of bromodomain-containing 4 by AZD5153 and BCL2 by AZD4320 against B-cell lymphomas concomitantly overexpressing c-MYC and BCL2. Takimoto-Shimomura T; Tsukamoto T; Maegawa S; Fujibayashi Y; Matsumura-Kimoto Y; Mizuno Y; Chinen Y; Shimura Y; Mizutani S; Horiike S; Taniwaki M; Kobayashi T; Kuroda J Invest New Drugs; 2019 Apr; 37(2):210-222. PubMed ID: 29931583 [TBL] [Abstract][Full Text] [Related]
18. ARID1A-SIN3A drives retinoic acid-induced neuroblastoma differentiation by transcriptional repression of TERT. Bui CB; Le HK; Vu DM; Truong KD; Nguyen NM; Ho MAN; Truong DQ Mol Carcinog; 2019 Nov; 58(11):1998-2007. PubMed ID: 31365169 [TBL] [Abstract][Full Text] [Related]
19. Disruption of BRD4 at H3K27Ac-enriched enhancer region correlates with decreased c-Myc expression in Merkel cell carcinoma. Sengupta D; Kannan A; Kern M; Moreno MA; Vural E; Stack B; Suen JY; Tackett AJ; Gao L Epigenetics; 2015; 10(6):460-6. PubMed ID: 25941994 [TBL] [Abstract][Full Text] [Related]
20. TP63, SOX2, and KLF5 Establish a Core Regulatory Circuitry That Controls Epigenetic and Transcription Patterns in Esophageal Squamous Cell Carcinoma Cell Lines. Jiang YY; Jiang Y; Li CQ; Zhang Y; Dakle P; Kaur H; Deng JW; Lin RY; Han L; Xie JJ; Yan Y; Doan N; Zheng Y; Mayakonda A; Hazawa M; Xu L; Li Y; Aswad L; Jeitany M; Kanojia D; Guan XY; Said JW; Yang W; Fullwood MJ; Lin DC; Koeffler HP Gastroenterology; 2020 Oct; 159(4):1311-1327.e19. PubMed ID: 32619460 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]